Clinical Daily Summary: What Happened on October 6, 2026

Survodutide’s weight loss came with frequent treatment stops

The 755-person SYNCHRONIZE-2 trial compared weekly survodutide at two doses with placebo for 76 weeks in adults with overweight or obesity and type 2 diabetes.2 In an analysis assuming participants stayed on treatment, average weight loss reached 13.1%, versus 3.1% with placebo, and up to 79.3% lost at least 5% of their weight, versus 32.7%.2 When the analysis included outcomes regardless of treatment discontinuation, weight loss was 9.8% with the higher dose and 8.2% with the lower dose, compared with 3.9% on placebo.2

Survodutide lowered hemoglobin A1c, a measure of average blood sugar, by up to 1.21 percentage points from a baseline of 7.4%, compared with 0.03 points on placebo.2 Gastrointestinal events led 18% of survodutide recipients to stop treatment, compared with 1.2% of placebo recipients, usually during dose escalation.2 Boehringer Ingelheim said a fixed dose-escalation schedule may have contributed to the treatment stops. Newer trials allow more flexible dose increases, the company said.2

The trial did not compare survodutide with an approved incretin drug, so its performance against those treatments remains unknown.2 Survodutide is not approved, and the companies expect cardiovascular outcomes data from SYNCHRONIZE-CVOT later in 2026.12

Epcoritamab combination cuts lymphoma progression-or-death risk

An interim analysis of EPCORE DLBCL-2 found that epcoritamab plus R-CHOP reduced the risk of disease progression or death by 51% compared with R-CHOP alone.34 The combination significantly improved progression-free survival, the time patients live without their disease worsening or dying.3 The open-label trial compares the combination with R-CHOP alone, not with Polivy plus R-CHOP.34

The Independent Data Monitoring Committee recommended unblinding the study after observing the benefit.3 The companies said the safety profile was generally consistent with prior experience of the medicines.3 Epcoritamab is authorized in the European Union for some patients whose diffuse large B-cell lymphoma has returned or resisted at least two treatment regimens, but its use with R-CHOP for newly diagnosed disease remains unapproved.34 AbbVie and Genmab plan to present complete results at a future medical meeting and discuss next steps with regulators.3

Also worth knowing

• 

  Vial dosed the first participant in a Phase Ib asthma study of its bispecific antibody, which blocks IL-13 and TSLP. The trial will assess safety, tolerability, lung function and inflammation markers.5

• 

  A retinal-imaging AI platform predicted preeclampsia with an AUC of 0.81 in an independent cohort of 79 pregnancies, without retraining after development in 1,267 pregnancies.6

• N

  In follow-up of four people with relapsed or refractory multiple myeloma treated with in vivo BCMA CAR-T, all initially responded, but three relapsed within five months and later died. Median progression-free survival was four months.7

• B

  On October 5, the FDA approved Alvotech’s second Reykjavik production suite for SIMLANDI, doubling capacity available for US supply.8

• B

  On October 5, Novo Nordisk said the FDA extended its review of denecimig for hemophilia A while manufacturing-facility remediation continues. The company is targeting a possible US launch in the first half of 2027.8

• B

  On October 5, AMETHYST data showed skin improvements through 52 weeks with litifilimab in cutaneous lupus erythematosus. Phase 3 results are expected in the first half of 2027.8

Also published

• Where GLP-1 Development May be Headed Pharmaceutical Executive
• ACT Brief: Ibogaine Trial Design Guidance, Outsourcing Model Oversight Gaps, and Kidney Disease Partnership Applied Clinical Trials